Diadem Biotherapeutics
Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.
Diadem Biotherapeutics
BioLabs at The Lundquist Institute, 1124 W Carson St., MRL Building, 3rd FL, Torrance, CA 90502
Patents
What We Do
A proprietary platform for engineering extracellular vesicles to enable costimulatory activation or repression of immune cells, overcoming challenges in immune checkpoint agonism.
Application Area
Regenerative Medicine
Biologics
Key People
Scientist
News & Updates
Received the first Amgen Golden Ticket Award at BioLabs LA.
Secured $1.2 million in investment led by Novateur Ventures.
Successfully completed the Creative Destruction Lab startup mentorship program.
Participated in IndieBio's biotechnology accelerator program.
Selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.
Diadem Biotherapeutics was selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA.
With lead investment from Novateur Ventures, Diadem Biotherapeutics raised $1.2 million to develop immunotherapies.
Diadem Biotherapeutics completed the Creative Destruction Lab program, a nine-month startup mentorship initiative.
Diadem Biotherapeutics joined IndieBio, a leading biotechnology startup accelerator program.
Diadem Biotherapeutics was selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.